Artificial intelligence-driven drug repositioning uncovers efavirenz as a modulator of α-synuclein propagation : Implications in Parkinson's disease
Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved..
Parkinson's disease (PD) is a complex neurodegenerative disorder with an unclear etiology. Despite significant research efforts, developing disease-modifying treatments for PD remains a major unmet medical need. Notably, drug repositioning is becoming an increasingly attractive direction in drug discovery, and computational approaches offer a relatively quick and resource-saving method for identifying testable hypotheses that promote drug repositioning. We used an artificial intelligence (AI)-based drug repositioning strategy to screen an extensive compound library and identify potential therapeutic agents for PD. Our AI-driven analysis revealed that efavirenz and nevirapine, approved for treating human immunodeficiency virus infection, had distinct profiles, suggesting their potential effects on PD pathophysiology. Among these, efavirenz attenuated α-synuclein (α-syn) propagation and associated neuroinflammation in the brain of preformed α-syn fibrils-injected A53T α-syn Tg mice and α-syn propagation and associated behavioral changes in the C. elegans BiFC model. Through in-depth molecular investigations, we found that efavirenz can modulate cholesterol metabolism and mitigate α-syn propagation, a key pathological feature implicated in PD progression by regulating CYP46A1. This study opens new avenues for further investigation into the mechanisms underlying PD pathology and the exploration of additional drug candidates using advanced computational methodologies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:174 |
|---|---|
| Enthalten in: |
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie - 174(2024) vom: 20. März, Seite 116442 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kim, Jae-Bong [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
α-synuclein |
|---|
| Anmerkungen: |
Date Revised 21.03.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.biopha.2024.116442 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370031717 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370031717 | ||
| 003 | DE-627 | ||
| 005 | 20240323001851.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240323s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.biopha.2024.116442 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1341.xml |
| 035 | |a (DE-627)NLM370031717 | ||
| 035 | |a (NLM)38513596 | ||
| 035 | |a (PII)S0753-3322(24)00326-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kim, Jae-Bong |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Artificial intelligence-driven drug repositioning uncovers efavirenz as a modulator of α-synuclein propagation |b Implications in Parkinson's disease |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 21.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved. | ||
| 520 | |a Parkinson's disease (PD) is a complex neurodegenerative disorder with an unclear etiology. Despite significant research efforts, developing disease-modifying treatments for PD remains a major unmet medical need. Notably, drug repositioning is becoming an increasingly attractive direction in drug discovery, and computational approaches offer a relatively quick and resource-saving method for identifying testable hypotheses that promote drug repositioning. We used an artificial intelligence (AI)-based drug repositioning strategy to screen an extensive compound library and identify potential therapeutic agents for PD. Our AI-driven analysis revealed that efavirenz and nevirapine, approved for treating human immunodeficiency virus infection, had distinct profiles, suggesting their potential effects on PD pathophysiology. Among these, efavirenz attenuated α-synuclein (α-syn) propagation and associated neuroinflammation in the brain of preformed α-syn fibrils-injected A53T α-syn Tg mice and α-syn propagation and associated behavioral changes in the C. elegans BiFC model. Through in-depth molecular investigations, we found that efavirenz can modulate cholesterol metabolism and mitigate α-syn propagation, a key pathological feature implicated in PD progression by regulating CYP46A1. This study opens new avenues for further investigation into the mechanisms underlying PD pathology and the exploration of additional drug candidates using advanced computational methodologies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Drug repositioning | |
| 650 | 4 | |a Efavirenz | |
| 650 | 4 | |a Parkinson’s disease | |
| 650 | 4 | |a α-synuclein | |
| 700 | 1 | |a Kim, Soo-Jeong |e verfasserin |4 aut | |
| 700 | 1 | |a So, Minyoung |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Dong-Kyu |e verfasserin |4 aut | |
| 700 | 1 | |a Noh, Hye Rin |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Beom Jin |e verfasserin |4 aut | |
| 700 | 1 | |a Choi, Yu Ree |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Doyoon |e verfasserin |4 aut | |
| 700 | 1 | |a Koo, Heejung |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Taeyong |e verfasserin |4 aut | |
| 700 | 1 | |a Woo, Hyun Goo |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Sang Myun |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie |d 1984 |g 174(2024) vom: 20. März, Seite 116442 |w (DE-627)NLM012645591 |x 1950-6007 |7 nnns |
| 773 | 1 | 8 | |g volume:174 |g year:2024 |g day:20 |g month:03 |g pages:116442 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.biopha.2024.116442 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 174 |j 2024 |b 20 |c 03 |h 116442 | ||